CLOs on the Move

Haematologic Technologies

www.haemtech.com

 
A large molecule CRO combining world-class protein chemistry expertise, integrated large molecule analytical services, and coagulation reagents for biopharma R&D.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Quadrant Laboratories

Quadrant Laboratories is a subsidiary of Quadrant Biosciences, a life sciences company focused on improving the lives of children and families through innovative diagnostic, therapeutic, and virtual care solutions for global health priorities. Quadrant...

Dzeel Clinical

Dzeel Clinical is a Garner, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Atossa Genetics

Atossa Genetics is a healthcare company offering proprietary medical devices and laboratory services in women`s health. Our laboratory services are offered through our wholly owned subsidiary, the National Reference Laboratory for Breast Health (NRLBH)

Gradientech

Gradientech is developing the microfluidic platform of tomorrow, today. Our revolutionising in vitro diagnostic system, QuickMIC®, is designed to strengthen labs by providing reliable results, at outstanding speed. Visit to experience how.

Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals (NASDAQ: SBPH) is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using our proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that the company designs to selectively target and modulate the activity of specific proteins implicated in various disease states. Spring Bank is developing its most advanced SMNH product candidate, inarigivir soproxil (formerly referred to as SB 9200), for the treatment of viral diseases, including hepatitis B virus (HBV), and other SMNH product candidates, including SB 11285, the company`s lead immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of Interferon Genes, or STING, pathway.